All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2026-07-31.
From the record
Amgen Inc.'s filings since 2017 show 1 warning event: a material cybersecurity incident (8-K item 1.05, the latest 2026-07-31) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+7.8% a year over 7 filed years; profitable in 7 of 7.
From the record
Amgen Inc.'s 7 filed years say what it did: revenue went from $23 billion in fiscal 2019 to $37 billion in fiscal 2025, up 7.8% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 7 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 0.1% a year. 49% of cash flow returned. Insiders: 14 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Amgen Inc.'s diluted share count grew about 0.1% a year, and dividends and buybacks returned about 49% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 14 sales and 0 purchases of their own stock on the open market in the year to 2026-11-09 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 89%: 89¢ of profit per shareholder dollar. Leverage 90%: owes 90¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Amgen Inc. earned about 89 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 27 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 90 cents per dollar of assets, and net share issuance: its share count grew 0.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 19% of 102 in its family; net margin 21%.
From the record
Amgen Inc.'s standing among 102 graded names in its industry family: revenue of $37 billion in fiscal 2025 ranks in the top 1% by size; a net margin of 21% ranks in the top 13%; revenue growth of 11.8% a year over the last 3 filed years ranks in the top 44% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 9% of 110 in its family for leadership; chief executive since 2012.
From the record
Amgen Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Bradway, Robert A (Chairman, CEO and President, as filed), filing under that title since 2012-12-20, 13.9 years (top 3% of its family); the 24 officers and directors filing in the last fifteen months have been on the record a median of 8.2 years (top 8%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 24 people in charge now (top 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 40% of 92 in its family for room to expand.
From the record
Amgen Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $9.1 billion against debt of $55 billion leaves -50.2% of its assets as net cash, bottom 2% of its family; cash from operations less capital spending is 22% of revenue (top 9%); a gross margin of 67.2% (top 50%); research spending of 19.8% of revenue (bottom 17%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 27% of 100 in its family for growth drivers.
From the record
Amgen Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 11.8% a year over the last three filed years against 7.8% over all 7, speeding up (top 23% of its family); the newest year grew 10% (bottom 47%); research spending grew 17.9% a year (top 20%); capital spending grew 25.7% a year (top 14%) (its annual reports). Amgen Inc. reported 16 product lines in fiscal 2025: Other Products at $7.3 billion (20%), Prolia at $4.4 billion (12%), Repatha at $3.0 billion (8%), and 13 more; 13 of 16 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 48% of 72 in its family for expectations against reality.
From the record
Amgen Inc.'s newest year against its own record: revenue of $37 billion in fiscal 2025 came in 2.4% below the $38 billion its prior three years' pace pointed to (bottom 44% of its family); net income of $7.7 billion against a prior three-year average of $5.8 billion (top 36%); a net margin of 21% against 20.3% before (bottom 35%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made